Filing Details

Accession Number:
0001209191-23-024312
Form Type:
4
Zero Holdings:
No
Publication Time:
2023-04-14 16:19:24
Reporting Period:
2023-04-12
Accepted Time:
2023-04-14 16:19:24
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
875320 Vertex Pharmaceuticals Inc / Ma VRTX Pharmaceutical Preparations (2834) 043039129
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1829069 Bastiano Sanna C/O Vertex Pharmaceuticals Incorporated
50 Northern Avenue
Boston MA 02210
Evp, Cell & Genetic Therapies No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2023-04-12 874 $325.70 46,406 No 4 S Direct
Common Stock Disposition 2023-04-12 4,068 $326.45 42,338 No 4 S Direct
Common Stock Disposition 2023-04-12 2,625 $327.43 39,713 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
No 4 S Direct
No 4 S Direct
Footnotes
  1. Transaction made pursuant to Mr. Sanna's company approved trading plan under Rule 10b5-1, which was entered into on 08/10/2022.
  2. Mr. Sanna undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
  3. Open market sales reported on this line occurred at a weighted average price of $325.70 (range $325.00 to $325.98).
  4. Open market sales reported on this line occurred at a weighted average price of $326.45 (range $326.00 to $326.99).
  5. Open market sales reported on this line occurred at a weighted average price of $327.43 (range $327.01 to $327.91).